NCT04132479 is a Phase 4 clinical trial of Clarithromycin 500mg in Helicobacter Pylori Infection, sponsored by Kirby Institute.

Who is sponsoring NCT04132479?

NCT04132479 is sponsored by Kirby Institute.

What drugs are being tested in NCT04132479?

Interventions in NCT04132479: Clarithromycin 500mg, Amoxicillin 500mg, Tinidazole 500mg, Rabeprazole 20mg, Clarithromycin 500mg, Amoxicillin 500mg, Tinidazole 500mg, Rabeprazole 20mg.

What condition does NCT04132479 study?

NCT04132479 studies Helicobacter Pylori Infection.

Is NCT04132479 still recruiting?

NCT04132479 is currently completed. Last updated 18 October 2019.

Last reviewed 2019-10-18 · How we verify

NCT04132479

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

The Epidemiology and Optimal Treatment of Helicobacter Pylori in Myanmar

Completed Phase 4 Last updated 18 October 2019

What this trial tests

Phase 4 trial testing Clarithromycin 500mg in Helicobacter Pylori Infection in 313 participants. Completed in 9 April 2019.

Timeline

1 January 2018

Primary endpoint
31 December 2018

9 April 2019

Quick facts

Lead sponsor	Kirby Institute
Phase	Phase 4
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	313
Start date	1 January 2018
Primary completion	31 December 2018
Estimated completion	9 April 2019
Sites	1 location across Burma

Drugs / interventions tested

Clarithromycin 500mg — full drug profile →
Amoxicillin 500mg — full drug profile →
Tinidazole 500mg — full drug profile →
Rabeprazole 20mg
Clarithromycin 500mg — full drug profile →
Amoxicillin 500mg — full drug profile →
Tinidazole 500mg — full drug profile →
Rabeprazole 20mg

Conditions studied

Helicobacter Pylori Infection — all drugs for Helicobacter Pylori Infection →

Sponsor

Kirby Institute

Who can join

12 and older, any sex, with Helicobacter Pylori Infection. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study aims to: 1. Determine the prevalence of Helicobacter infection in Myanmar (this would be the largest ever series in the country) 2. Determine the clinical and epidemiological associations of Helicobacter infection in Myanmar 3. Determine the utility of stool antigen testing to diagnose the infection and confirm eradication 4. Compare the relative efficacies of concomitant and sequential therapy 5. Determine the relative efficacies of first, second and third line therapies in Myanmar in 2018

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Clarithromycin 500mg

Trials testing the same drug.

NCT06294600 — Clarithromycin Treatment to Prevent Sepsis Progression in CAP (REACT) · Phase 3 · recruiting
NCT06751121 — Study to Evaluate the Efficacy and Safety of DWP14012-based Triple Therapy in Eradication of Helicobacter Pylori · Phase 3 · completed
NCT05991401 — Evaluate the Effect of Clarithromycin/Rifampicin on the Pharmacokinetics of DA-8010 in Healthy Adults · Phase 1 · completed
NCT04724044 — Anti-inflammatory Action of Oral Clarithromycin in Community-acquired Pneumonia · Phase 3 · completed
NCT04622891 — Clarithromycin Versus Azithromycin in Treatment of Mild COVID-19 Infection · NA · completed

Other recruiting trials for Helicobacter Pylori Infection

Currently open trials in the same condition.

NCT07285096 — P-CABs-based Bismuth Quadruple Therapy for Helicobacter Pylori Eradication · recruiting
NCT07358130 — Efficacies of Bismuth-amoxicillin-vonoprazan Triple Therapy and Bismuth Quadruple Therapy · NA · recruiting
NCT07165444 — Potassium-Competitive Acid Blocker Versus Proton Pump Inhibitor as A Part of Bismuth Based Quadruple Therapy for Treatme · NA · recruiting
NCT06929962 — VA Dual Sequential Therapy · Phase 4 · recruiting
NCT06959368 — Vonoprazan Evaluation Compared to Standard Triple Therapy in Helicobacter Pylori eRadication · Phase 4 · recruiting

Other Kirby Institute trials

Trials by the same sponsor.

NCT07145736 — Moxidectin Versus Ivermectin as Mass Drug Administration for the Control of Onchocerciasis and Other Neglected Tropical · Phase 4 · recruiting
NCT06220370 — PATH Study: People With Injecting Related Infections: Assessing Treatment Outcomes for Those Who Are Hospitalised. · not yet recruiting
NCT05415267 — Immunosuppression and COVID-19 Boosters · Phase 3 · recruiting
NCT05144776 — Evaluation of Hepatitis B Virus (HBV) DNA Test As Point of Care Tool · completed
NCT04014179 — Enhancing Hepatitis C Testing and Treatment Among People Who Inject Drugs Attending Needle and Syringe Programs · NA · active not recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04132479 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Kirby Institute
Last refreshed: 18 October 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04132479.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing